Imfinzi Regimen Demonstrates Survival Benefit in Early Gastric and GEJ Cancer
The Phase III MATTERHORN trial has shown a 22% reduction in the risk of death for patients with early-stage gastric and gastroesophageal cancers.
Nancy Ghattas, VP, US Oncology Commercial Franchise Head of Immuno-Oncology at AstraZeneca, discussed the trial's results, highlighting the Imfinzi-based perioperative regimen's ability to improve overall survival regardless of PD-L1 status.
The Imfinzi-based perioperative regimen demonstrated a 22% reduction in the risk of death and improved overall survival.
This marks the first immunotherapy in this setting to show such benefit, redefining outcomes for patients with early-stage gastric and gastroesophageal cancers.
Author's summary: Imfinzi regimen shows 22% survival benefit.
More News
- SMAT 2025-26 | Pondicherry humbles Bengal; Baroda, sans Hardik, loses to Haryana
- Inside Denmark: No cuts on food tax could be a disappointment all round
- '350 looks good, but...': KL Rahul after four-wicket loss to South Africa in second ODI
- Ashes: Weatherald, Smith lead Australian charge at Brisbane
- Labour Party has abandoned women and feminism
- Alaska SuperTour Fairbanks – 10km Interval Start Classic
- Government accused of delaying crucial single-sex spaces guidance
- All Allround Mess: Lack of Clarity Scuttling Washington, Reddy and India
- Andries Gous Shines as Desert Vipers Secure Four-Wicket Victory Against Dubai Capitals in ILT20
- Government accused of delaying crucial guidance on Supreme Court ruling